Maslinic acid solid lipid nanoparticles as hydrophobic anticancer drug carriers: Formulation, in vitro activity and in vivo biodistribution
Maslinic acid (MA) is a natural pentacyclic triterpenoid with inherent antitumor activity which has a very low solubility in water. MA solid lipid nanoparticles (SLNs) were prepared using Poloxamer 407 and Dicarboxylic acid-Poloxamer 407 as surfactants. Both MA SLNs are monodisperse, with sizes arou...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-07-01
|
| Series: | Biomedicine & Pharmacotherapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332223006182 |
| _version_ | 1797822131727237120 |
|---|---|
| author | Aixa Aguilera-Garrido Pablo Graván Saúl A. Navarro-Marchal Marta Medina-O’Donnell Andrés Parra María José Gálvez-Ruiz Juan Antonio Marchal Francisco Galisteo-González |
| author_facet | Aixa Aguilera-Garrido Pablo Graván Saúl A. Navarro-Marchal Marta Medina-O’Donnell Andrés Parra María José Gálvez-Ruiz Juan Antonio Marchal Francisco Galisteo-González |
| author_sort | Aixa Aguilera-Garrido |
| collection | DOAJ |
| description | Maslinic acid (MA) is a natural pentacyclic triterpenoid with inherent antitumor activity which has a very low solubility in water. MA solid lipid nanoparticles (SLNs) were prepared using Poloxamer 407 and Dicarboxylic acid-Poloxamer 407 as surfactants. Both MA SLNs are monodisperse, with sizes around 130 nm, and stable. Curcumin has been encapsulated in both types of nanoparticles without altering their colloidal properties. Moreover, SLNs greatly improve the solubility of MA and Curcumin. The cytotoxicity of MA and SLNs has been evaluated in BxPC3 human pancreatic cancer cells, MCF7 human breast cancer cells, and in a human fibroblast primary cell line. MA shows higher cytotoxic effect in BxPC3 and MCF7 cancer cells than in human primary fibroblasts. Nile Red loaded MA SLNs are quickly uptaken by BxPC3 and MCF7 cells, and show different cytoplasmic distributions depending on the cellular line. The oral or intravenous administration of MA SLNs in mice does not report any toxic effect, and the intravenous administration of fluorescent MA SLNs shows a homogeneous distribution in mice, without site-specific accumulation. Results suggest the great potential of MA SLNs as nanocarriers of anticancer drugs and as promising targeted theranostic nanodevices. |
| first_indexed | 2024-03-13T10:03:24Z |
| format | Article |
| id | doaj.art-9f25c8bf1c8d4f0692345791e49d69e9 |
| institution | Directory Open Access Journal |
| issn | 0753-3322 |
| language | English |
| last_indexed | 2024-03-13T10:03:24Z |
| publishDate | 2023-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biomedicine & Pharmacotherapy |
| spelling | doaj.art-9f25c8bf1c8d4f0692345791e49d69e92023-05-23T04:21:13ZengElsevierBiomedicine & Pharmacotherapy0753-33222023-07-01163114828Maslinic acid solid lipid nanoparticles as hydrophobic anticancer drug carriers: Formulation, in vitro activity and in vivo biodistributionAixa Aguilera-Garrido0Pablo Graván1Saúl A. Navarro-Marchal2Marta Medina-O’Donnell3Andrés Parra4María José Gálvez-Ruiz5Juan Antonio Marchal6Francisco Galisteo-González7Department of Applied Physics, University of Granada, Fuentenueva, s/n, Granada 18071, Spain; Excellence Research Unit Modelling Nature (MNat), University of Granada, Fuentenueva, s/n, Granada 18071, SpainDepartment of Applied Physics, University of Granada, Fuentenueva, s/n, Granada 18071, Spain; Excellence Research Unit Modelling Nature (MNat), University of Granada, Fuentenueva, s/n, Granada 18071, Spain; Department of Human Anatomy and Embryology, Faculty of Medicine, University of Granada, Granada 18016, Spain; Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), University of Granada, Granada 18012, Spain; Biopathology and Regenerative Medicine Institute (IBIMER), Centre for Biomedical Research (CIBM), University of Granada, Granada 18016, Spain; BioFab i3D, Biofabrication and 3D (bio)printing laboratory, University of Granada, Granada 18100, SpainExcellence Research Unit Modelling Nature (MNat), University of Granada, Fuentenueva, s/n, Granada 18071, Spain; Biopathology and Regenerative Medicine Institute (IBIMER), Centre for Biomedical Research (CIBM), University of Granada, Granada 18016, Spain; Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UKDepartment of Organic Chemistry, University of Granada, Fuentenueva, s/n, Granada 18071, SpainDepartment of Organic Chemistry, University of Granada, Fuentenueva, s/n, Granada 18071, SpainDepartment of Applied Physics, University of Granada, Fuentenueva, s/n, Granada 18071, Spain; Excellence Research Unit Modelling Nature (MNat), University of Granada, Fuentenueva, s/n, Granada 18071, SpainExcellence Research Unit Modelling Nature (MNat), University of Granada, Fuentenueva, s/n, Granada 18071, Spain; Department of Human Anatomy and Embryology, Faculty of Medicine, University of Granada, Granada 18016, Spain; Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), University of Granada, Granada 18012, Spain; Biopathology and Regenerative Medicine Institute (IBIMER), Centre for Biomedical Research (CIBM), University of Granada, Granada 18016, Spain; BioFab i3D, Biofabrication and 3D (bio)printing laboratory, University of Granada, Granada 18100, Spain; Correspondence to: Dpt. of Applied Physics, University of Granada, Fuentenueva s/n, Granada 18071, Spain.Department of Applied Physics, University of Granada, Fuentenueva, s/n, Granada 18071, Spain; Excellence Research Unit Modelling Nature (MNat), University of Granada, Fuentenueva, s/n, Granada 18071, Spain; Correspondence to: Dpt. of Applied Physics, University of Granada, Fuentenueva s/n, Granada 18071, Spain.Maslinic acid (MA) is a natural pentacyclic triterpenoid with inherent antitumor activity which has a very low solubility in water. MA solid lipid nanoparticles (SLNs) were prepared using Poloxamer 407 and Dicarboxylic acid-Poloxamer 407 as surfactants. Both MA SLNs are monodisperse, with sizes around 130 nm, and stable. Curcumin has been encapsulated in both types of nanoparticles without altering their colloidal properties. Moreover, SLNs greatly improve the solubility of MA and Curcumin. The cytotoxicity of MA and SLNs has been evaluated in BxPC3 human pancreatic cancer cells, MCF7 human breast cancer cells, and in a human fibroblast primary cell line. MA shows higher cytotoxic effect in BxPC3 and MCF7 cancer cells than in human primary fibroblasts. Nile Red loaded MA SLNs are quickly uptaken by BxPC3 and MCF7 cells, and show different cytoplasmic distributions depending on the cellular line. The oral or intravenous administration of MA SLNs in mice does not report any toxic effect, and the intravenous administration of fluorescent MA SLNs shows a homogeneous distribution in mice, without site-specific accumulation. Results suggest the great potential of MA SLNs as nanocarriers of anticancer drugs and as promising targeted theranostic nanodevices.http://www.sciencedirect.com/science/article/pii/S0753332223006182Maslinic acidCurcuminSolid lipid nanoparticlesPoloxamerPancreatic cancerBreast cancer |
| spellingShingle | Aixa Aguilera-Garrido Pablo Graván Saúl A. Navarro-Marchal Marta Medina-O’Donnell Andrés Parra María José Gálvez-Ruiz Juan Antonio Marchal Francisco Galisteo-González Maslinic acid solid lipid nanoparticles as hydrophobic anticancer drug carriers: Formulation, in vitro activity and in vivo biodistribution Biomedicine & Pharmacotherapy Maslinic acid Curcumin Solid lipid nanoparticles Poloxamer Pancreatic cancer Breast cancer |
| title | Maslinic acid solid lipid nanoparticles as hydrophobic anticancer drug carriers: Formulation, in vitro activity and in vivo biodistribution |
| title_full | Maslinic acid solid lipid nanoparticles as hydrophobic anticancer drug carriers: Formulation, in vitro activity and in vivo biodistribution |
| title_fullStr | Maslinic acid solid lipid nanoparticles as hydrophobic anticancer drug carriers: Formulation, in vitro activity and in vivo biodistribution |
| title_full_unstemmed | Maslinic acid solid lipid nanoparticles as hydrophobic anticancer drug carriers: Formulation, in vitro activity and in vivo biodistribution |
| title_short | Maslinic acid solid lipid nanoparticles as hydrophobic anticancer drug carriers: Formulation, in vitro activity and in vivo biodistribution |
| title_sort | maslinic acid solid lipid nanoparticles as hydrophobic anticancer drug carriers formulation in vitro activity and in vivo biodistribution |
| topic | Maslinic acid Curcumin Solid lipid nanoparticles Poloxamer Pancreatic cancer Breast cancer |
| url | http://www.sciencedirect.com/science/article/pii/S0753332223006182 |
| work_keys_str_mv | AT aixaaguileragarrido maslinicacidsolidlipidnanoparticlesashydrophobicanticancerdrugcarriersformulationinvitroactivityandinvivobiodistribution AT pablogravan maslinicacidsolidlipidnanoparticlesashydrophobicanticancerdrugcarriersformulationinvitroactivityandinvivobiodistribution AT saulanavarromarchal maslinicacidsolidlipidnanoparticlesashydrophobicanticancerdrugcarriersformulationinvitroactivityandinvivobiodistribution AT martamedinaodonnell maslinicacidsolidlipidnanoparticlesashydrophobicanticancerdrugcarriersformulationinvitroactivityandinvivobiodistribution AT andresparra maslinicacidsolidlipidnanoparticlesashydrophobicanticancerdrugcarriersformulationinvitroactivityandinvivobiodistribution AT mariajosegalvezruiz maslinicacidsolidlipidnanoparticlesashydrophobicanticancerdrugcarriersformulationinvitroactivityandinvivobiodistribution AT juanantoniomarchal maslinicacidsolidlipidnanoparticlesashydrophobicanticancerdrugcarriersformulationinvitroactivityandinvivobiodistribution AT franciscogalisteogonzalez maslinicacidsolidlipidnanoparticlesashydrophobicanticancerdrugcarriersformulationinvitroactivityandinvivobiodistribution |